Controversies in Management of Life-Threatening Bleeding in the Anticoagulated Patient: When is it Appropriate to Use an Antidote for GI Bleeding? - Program #5

Monday, November 1, 2021, 12:00 AM - Tuesday, November 1, 2022, 11:00 PM

AMA PRA Category 1 Credits™ (0.75 hours), AMA PRA Category 1 Credits™ Designated (0.75 hours)


As the utilization of direct oral anticoagulants (DOACs) increases, there is a parallel increase in major bleeding events, especially intracranial hemorrhages, requiring hospitalization. Clinicians are not recognizing or distinguishing major from minor bleeding, or appropriately employing emergent options to manage major bleeding. Recent solutions for DOAC related life-threatening bleeding are under-recognized and under-utilized solutions for patients with these life-threatening emergencies. Over the last 12-18 months, nationally recognized guidelines have provided clear direction on how best to manage these types of major bleeding events. As data emerges regarding new approaches to therapy, clinicians need to be aware of these new and effective approaches and to assess the benefits and risks associated with each of these approaches. Education provided by experts from the EMCREG-International network within this program correctly and promptly address patient treatment approaches to the appropriate healthcare professionals.


This program covers the optimal management of gastrointestinal bleeding in the anticoagulated patient, highlighting key considerations on when to use repletion or reversal therapy when these patients present to the ED or ICU.

To view this enduring material, please go to: https://www.mededonthego.com/

This activity is FREE to all participants.

1. Evaluate appropriateness of a reversal strategy in the presence of DOAC-related bleed
2. Demonstrate learning on reversal to case situations in the emergent setting
3. Recognize risk factors associated with DOAC-related bleeding

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati Office of Continuing Medical Education, EMCREG-International and TotalCME, Inc.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this online activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Continuing Nurse Education
Approved contact hours: 0.75 total continuing education contact hour for nurses are approved by the Ohio Board of Nursing through the OBN Approver Unit at the University of Cincinnati College of Nursing, Continuing Education Program (OBN-011-93). Contact hours are valid in most states. Program:

Continuing Pharmacy Education
The University of Cincinnati James L. Winkle College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0050-9999-21-039-H01-P. Activity type: Knowledge. This activity is worth a total of 0.75 CEUs (0.075 contact hour). 
Note: Pharmacists must complete all episodes in this activity to claim credit.

Please contact the James L. Winkle College of Pharmacy Continuing Pharmacy Education Office at
513-558-4716 or [email protected] with questions or concerns.


The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development. 

Mitigation of Relevant Financial Relationships

The University of Cincinnati adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests) over the last 24-months. All relevant relationships have been mitigated prior to the commencement of the activity.

Information regarding the new updated ACCME Standards for Integrity and Independence in Accredited Continuing Education can be found on the ACCME website.

No faculty are available for this activity at this time.

This activity is supported in part by an independent educational grant from Alexion Pharmaceuticals, Inc.